CDX-011 + Capecitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Conditions
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Trial Timeline
Nov 1, 2013 → Aug 7, 2018
NCT ID
NCT01997333About CDX-011 + Capecitabine
CDX-011 + Capecitabine is a phase 2 stage product being developed by Celldex Therapeutics for Metastatic gpNMB Over-expressing Triple Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01997333. Target conditions include Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01997333 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic gpNMB Over-expressing Triple Negative Breast Cancer